TWM560924U - Liquid supply device for human body insulin infusion - Google Patents

Abstract

A liquid supply device for injecting human body insulin has a carrier on which a liquid storage chamber and a flow guiding actuation unit are arranged, and a sensor and a driving wafer are mounted. The flow guiding actuating unit has a liquid guiding passage connecting the liquid storage outlet of the liquid storage chamber and a liquid guiding outlet. The sensor is in contact with human skin to monitor the monitored value of blood glucose levels in the sweat. The driving chip receives the monitoring value interpretation from the sensor, thereby controlling the actuation of the flow guiding actuating unit, and controlling the switching state of the valve switch of the liquid storage outlet and the liquid guiding outlet. After the flow-guiding actuation unit is driven, a pressure gradient is generated, so that the insulin liquid in the liquid storage chamber is output to the liquid-conducting outlet via the catheter, and flows into the micro-needle patch attached to the lower side of the flow-guiding unit. A plurality of hollow microneedles are injected into the subcutaneous tissue.

Description

Liquid supply device for human insulin injection

The present invention relates to a liquid supply device, and more particularly to a liquid supply device for human insulin injection.

At present, the treatment of type 1 diabetes and type 2 diabetes is mainly to supplement hypoglycemic drugs, including oral, syringe injection and insulin pump injection. Among them, oral and syringe injection methods, patients need to use their own blood glucose meter to test their own blood glucose level, and then take the drug according to the blood glucose level. The insulin pump system consists of an indwelling needle and an insulin pump. The indwelling needle is placed in the body and fixed on the body surface for blood collection and drug injection. The insulin pump connected to the indwelling needle controls the release of the hypoglycemic agent according to the blood glucose level.

Because insulin cannot be taken orally, it can only be injected. Syringe injection and the indwelling needle of the insulin pump not only cause pain to the patient during the injection, but also leave pinholes on the body surface. In particular, syringe injections often require multiple times a day, causing subcutaneous tissue to produce lumps due to frequent injections. The use of the insulin pump for the indwelling needle reduces the number of injections, but the overall assembly has a certain volumetric weight, which is inconvenient to carry around, and the setting on the body will affect the patient's daily life and exercise.

In view of the above-mentioned shortcomings, the present invention develops a safe, portable and painless intelligent human body insulin injection device, which provides a patient with daily injection of human insulin to control the blood glucose level at any time, and solves the above-mentioned conventional injection method.

The main purpose of this case is to provide a liquid supply device for human insulin injection, in order to solve The traditional insulin injection method can cause the patient's pain and inconvenience to carry around. It provides a safe, portable and painless intelligent human body insulin injection device, allowing patients to inject human insulin in daily life to control the blood glucose level at any time. Used as an artificial pancreas that automatically replenishes human insulin.

In order to achieve the above object, a broader aspect of the present invention provides a liquid supply device for injecting human insulin, comprising: a carrier; a reservoir chamber, on the carrier for storing an insulin liquid, and having a a liquid storage outlet; a flow guiding actuating unit, configured on the carrier, has a liquid guiding passage, communicates with the liquid discharging outlet of the liquid storage chamber, and communicates with a liquid guiding outlet to drive the flow guiding actuating unit The insulin liquid is delivered by the liquid outlet; a plurality of valve switches, the liquid outlet and the liquid outlet are respectively closed with a valve switch to control the state of the switch; a microneedle patch is attached to the guide Below the moving unit, the liquid guiding outlet is closed and connected, and the liquid guiding outlet outputs the insulin liquid into the microneedle patch, and the microneedle patch has a plurality of hollow microneedles for minimally invasive insertion into human skin. The insulin liquid is injected into the subcutaneous tissue; a sensor is disposed on the carrier to interfere with the human skin to monitor the blood sugar level in the sweat, and generate a monitoring value; a movable chip disposed on the carrier to control actuation of the flow guiding actuation unit, control a switching state of the plurality of valve switches, and receive the monitored value interpretation of the sensor; thereby, the microneedle sticker When the plurality of hollow microneedles are minimally invasively inserted into the human skin, and the sensor monitors the monitoring value of a specific blood glucose level in the sweat flowing out of the human skin, the driving current control unit is controlled by the driving wafer Simultaneously, the valve switch for controlling the liquid outlet is opened, and the valve switch of the liquid outlet is opened, so that the insulin liquid stored in the liquid storage chamber is output from the liquid outlet and introduced into the microneedle patch. The insulin liquid is injected into the subcutaneous tissue by the plurality of hollow microneedle-derived injections.

100‧‧‧Liquid supply device for human insulin injection

200‧‧‧ insulin liquid

300‧‧‧ valve layer

1‧‧‧ Carrier

11‧‧‧ Cover

12‧‧‧Cover parts

13a, 13b‧‧‧ chamber

14a, 14b‧‧‧ convex structure

2‧‧‧Liquid chamber

21‧‧‧Liquid outlet

3‧‧‧drain actuation unit

31‧‧‧ catheter channel

311‧‧‧ Entrance Channel

312‧‧‧Export channel

313‧‧‧pressure chamber

314‧‧‧ liquid outlet

32‧‧‧Actuator

321‧‧‧Carrier

322‧‧‧Acoustic

33a, 33b‧‧‧ valve

331a, 331b‧‧‧ Central Department

332a, 332b‧‧‧ Connections

333a, 333b‧‧‧ gap

4a, 4b‧‧‧valve switch

41‧‧‧ Holder

411‧‧‧through hole

42‧‧‧Seal

421‧‧‧through hole

43‧‧‧ displacement parts

431‧‧‧through hole

5‧‧‧Microneedle patch

51‧‧‧ hollow microneedles

52‧‧‧SMD area

6‧‧‧ sensor

7‧‧‧Drive chip

1 is a structural diagram of a liquid supply device for injecting human insulin in a preferred embodiment of the present invention. intention.

2A and 2B are schematic views showing the operation of the valve switch in a preferred embodiment of the present invention.

Figure 3 is a schematic view showing the application of the liquid supply device for human insulin injection in a preferred embodiment of the present invention.

Figure 4 is a block diagram showing the electrical connection relationship of the components of the liquid supply device for injecting human insulin in a preferred embodiment of the present invention.

5A and 5B are schematic views showing the operation of the liquid supply device for injecting human insulin in a preferred embodiment of the present invention.

Figure 6 is a schematic view showing the structure of the valve sheet layer in a preferred embodiment of the present invention.

Some exemplary embodiments embodying the features and advantages of the present invention are described in detail in the following description. It is to be understood that the present invention is capable of various modifications in various aspects, and is not to be construed as a limitation.

Please refer to FIG. 1 , which is a schematic structural view of a liquid supply device for injecting human insulin in a preferred embodiment of the present invention. The liquid supply device 100 for human insulin injection comprises a carrier 1 and a liquid storage chamber 2, a flow guiding actuation unit 3, valve switches 4a and 4b, a microneedle patch 5, a sensor 6 and a structure mounted on the carrier 1 The wafer 7 is driven. The carrier 1 can be, but is not limited to, a germanium wafer or a PCB circuit board, and the sensor 6 and the driving wafer 7 can be integrated on the carrier 1 by a microelectromechanical process (MEMS). Further, a reservoir chamber 2 is recessed in the carrier 1 for storing the human insulin liquid 200, and has a liquid storage outlet 21, and the liquid storage chamber 2 is recessed on the carrier 1 and sealed by a cover plate 11.

The flow guiding actuation unit 3 of the present embodiment includes a fluid guiding channel 31 and an actuator 32. The structure of the liquid guiding channel 3 is formed inside the carrier 1 and has an inlet passage 311 and a pressure chamber. 313, an outlet channel 312 and a liquid outlet 314. The liquid guiding passage 31 is a fluid passage that communicates with the liquid storage outlet 21 and the liquid guiding outlet 314. More specifically, the carrier 1 is disposed to be spaced apart from each other by an inlet passage 311 and an outlet passage 312, and a pressure chamber 313 is respectively connected to one end of the inlet passage 311 and the outlet passage 312, and above the pressure chamber 313 It is sealed by the actuator 32. The other end of the inlet passage 311 communicating with the pressure chamber 313 is covered with a cover member 12 such that the other end communicates with the liquid storage outlet 21 of the liquid storage chamber 2 to form a sealed fluid passage, and the outlet passage 312 communicates with the pressure chamber. The opening formed at the other end of the chamber 313 is the liquid guiding outlet 314. The liquid guiding passage 31 of the flow guiding actuating unit 3 is a fluid passage formed by the inlet passage 311, the pressure chamber 313, the outlet passage 312, and the liquid guiding outlet 314 in series.

The actuator 32 of the present embodiment is composed of a carrier member 321 and an actuating member 322. The carrier member 321 is a flexible plate member, and the cover pressure chamber 313 is fixed to the carrier 1. The actuating member 322 is a plate-shaped piezoelectric element attached to the upper surface of the carrier 321 . The actuating element 322 is deformed by a voltage application, and the interlocking carrier 321 deforms and resonates, thereby amplifying or compressing the volume of the pressure chamber 313 to form a pressure gradient for driving the insulin liquid 200 stored in the liquid storage chamber 2 to be introduced at the inlet. The passage 311 and the outlet passage 312 flow.

The valve switches 4a and 4b of the present embodiment are respectively disposed on the liquid storage outlet 21 and the liquid-conducting outlet 314, and the switching state is controlled by the driving wafer 7. Please refer to FIG. 2A and FIG. 2B, which is one of the preferred examples. The actuation diagram of the valve switch in the embodiment. When the drive wafer 7 controls the flow-guiding actuation unit 3 to be activated, the valve switches 4a, 4b are also opened; when the drive wafer 7 controls the flow-guiding actuation unit 3 to stop acting, the valve switches 4a, 4b are closed. The valve switch 4a and the valve switch 4b have the same configuration. To avoid repeating the description of the same configuration, only the valve switch 4a will be described below as an example. The valve switch 4a includes a sealing member 41, a holding member 42, and a displacement member 43. The sealing member 41 and the holding member 42 respectively have a plurality of through holes 411 and 421. The displacement member 43 is disposed in the accommodating space formed between the sealing member 41 and the holding member 42 and has a plurality of holes. Through hole 431. The through hole 431 of the displacement member 43 is substantially aligned with the through hole 421 of the holder 42 and is misaligned with the through hole 411 of the sealing member 41.

In the first embodiment of the valve switch 4a of the present embodiment, the displacement member 43 can be a charged material, and the holder 41 can be a two-polar conductive material. In the second embodiment of the valve switch 4a of the present embodiment, the displacement member 43 can be a magnetic material, and the holder 41 can be a magnetic material of controlled polarity. As shown in Fig. 2A, when the driving wafer 7 controls the holding member 42 to maintain the same polarity as the displacement member 43, the displacement member 43 approaches toward the sealing member 41, constituting the closing of the valve switch 4a. As shown in Fig. 2B, when the driving wafer 7 controls the holding member 41 to maintain a polarity different from that of the displacement member 43, the displacement member 43 approaches the holder 41 to constitute the opening of the valve switch 4a.

The microneedle patch 5 of the embodiment has a plurality of hollow microneedles 51 and a patch area 52, and the patch area 52 is a viscous sheet, and the microneedle patch 5 can be attached to the adhesive layer 52 by adhesion. The carrier 1 is covered with a cover member 12, and the entire microneedle patch 5 is fixed on the carrier 1 with the liquid-conducting outlet 314 side, and the liquid-conducting outlet 314 is connected to the hollow micro-needle 51, and the patch region 52 can also be utilized. One side of the adhesive is attached to the skin of the user, and the liquid supply device 100 for injecting the entire body of insulin is positioned on the skin of the user without falling. The hollow microneedle 51 is a micron-sized fine needle capable of piercing the skin, and the material thereof may be a high molecular polymer, a metal or a ruthenium, preferably a cerium oxide having high biocompatibility. The pore size of the hollow microneedle 51 can be passed through the insulin molecule. Preferably, the inner diameter of the hollow microneedle 51 is between 10 micrometers (μm) and 550 micrometers (μm), and the length of the hollow microneedle 51 is 400 micrometers (μm). ) to 900 micrometers (μm), can be inserted into the subcutaneous tissue of the human body and the penetration depth does not touch the human nerve, so there is no pain at all. A plurality of hollow microneedles 51 are arranged on the microneedle patch 5 in an array, and each of the hollow microneedles 51 is adjacent to each other by more than 200 micrometers (μm) to ensure that the hollow microneedles 51 can penetrate the skin smoothly. The plurality of hollow microneedles 51 arranged in such an array manner does not affect the insulin injection due to the blockage of one of the hollow microneedles 51, because the other hollow microneedles 51 can Continue to keep injecting insulin.

Please refer to FIG. 3, which is a schematic diagram of the application of the liquid supply device for human insulin injection in a preferred embodiment of the present invention. As shown in the figure, since the liquid supply device 100 for injecting human insulin is in a thin plate shape and has a micro size, the patch region 52 of the microneedle patch 5 can be adhesively attached to the human skin. In this way, the liquid supply device 100 for injecting human insulin can be fixed at any position on the human body by utilizing the adhesiveness of the patch region 52 alone.

Please refer to FIG. 1 and FIG. 4 at the same time. FIG. 4 is a block diagram showing the electrical connection relationship of the components of the liquid supply device for human insulin injection in a preferred embodiment of the present invention. The sensor 6 is disposed on the carrier 1 in a micro-electromechanical process. When the liquid supply device 100 for injecting human insulin is positioned on the skin of the user, the sensor 6 can interfere with the human skin and monitor the glucose content in the human sweat. This estimates the body's blood glucose level and produces a corresponding blood glucose monitoring value. The driving chip 7 is disposed on the carrier 1 in a microelectromechanical process, respectively coupled to the actuator 31 of the flow guiding actuating unit 3, the valve switches 4a and 4b, and the sensor 6, thereby transmitting a signal to control the flow guiding actuating unit 3 The actuator 31 is actuated and controls the switching states of the valve switches 4a and 4b and receives the monitored value interpretation from the sensor 6. In one embodiment of the present invention, the drive wafer 7 further includes a graphene battery to provide power.

Please refer to FIG. 5A and FIG. 5B , which are schematic diagrams showing the operation of the liquid supply device for injecting human insulin in a preferred embodiment of the present invention. When the sensor 6 senses a specific blood glucose level monitoring value, the driving wafer 7 transmits a start signal to the flow guiding actuating unit 3 to activate the actuator 32 while controlling the valve switches 4a and 4b to be turned on. The movable element 322 is deformed by the application of a voltage to cause an inverse piezoelectric effect, and the interlocking carrier 321 resonates. At this time, the actuator 32 reciprocates in a vertical direction. As shown in Fig. 5A, when the actuator 32 vibrates upward, the pressure chamber 313 is expanded to increase in volume, thereby generating a suction force that drives the insulin liquid 200 out of the liquid storage outlet 21 to be introduced into the pressure chamber 313. Next, as shown in FIG. 5B, when the actuator 32 is deformed downward, the body of the pressure chamber 313 is compressed. The insulin liquid 200 is squeezed and pushed downward to the outlet channel 312 to flow to the liquid outlet 314, and then introduced into the plurality of hollow microneedles 51 of the microneedle patch 5 to complete a certain amount of insulin. The liquid 200 is injected into the subcutaneous tissue of the human body. Of course, if it is necessary to re-inject the insulin liquid 200 to complete the required amount, repeating the above-mentioned actuator 32 up and down, the insulin liquid 200 can be continuously transported from the liquid storage outlet 21 through the liquid guiding channel 31 to the liquid guiding outlet 314 through the hollow microneedle. 51 is injected into the subcutaneous tissue of the human body and can be used as an artificial pancreas that automatically supplements human insulin.

In order to prevent backflow of the supply and delivery liquid, the liquid supply device 100 for human insulin injection in the present invention can further further provide a valve sheet layer 300 in the inlet passage 311 and the outlet passage 312 of the carrier 1 as shown in FIG. Please refer to FIG. 1 and FIG. 6 at the same time. FIG. 6 is a schematic structural view of a valve sheet layer in a preferred embodiment of the present invention. More specifically, the carrier 1 is respectively provided with a chamber 13 at a middle position of one of the inlet passage 311 and the outlet passage 312, and a valve sheet layer 300 is embedded in the carrier 1 to cover the inlet passage 311 and the outlet passage 312. As shown in Fig. 6, the valve plate layer 300 is composed of a flexible flat plate material, and valve plates 33a, 33b are formed at the corresponding cover inlet passage 311 and the outlet passage 312, respectively, and a central portion is defined on the valve piece 33a. The portion 331a is connected and supported by the plurality of connecting portions 332a on the valve sheet layer 300, and the plurality of connecting portions 332a separate the plurality of gaps 333a for liquid to circulate. The central portion 331a, the connecting portion 332a, and the gap 333a constitute the valve piece 33a. Similarly, the central portion 331b, the connecting portion 332b, and the gap 333b on the valve sheet layer 300 also constitute the valve piece 33b of the same structure.

In addition, as shown in FIG. 1 , the carrier 1 further has a protrusion structure 14 a , 14 b at the inlet channel 311 and the outlet channel 312 respectively. The protrusion structure 14 a is disposed at the inlet channel 311 and is disposed in the chamber. The bottom portion 13a; and the convex portion structure 14b is disposed at the outlet passage 312 and disposed at the top of the chamber 13b. The convex portion structures 14a, 14b can bring the central portions 331a, 331b of the valve sheets 33a, 33b into contact with each other to generate a pre-stressing action. By the above It is provided that when the actuator 31 is not actuated, the valve piece 33a can close the inlet passage 311, and the valve piece 33b closes the isolation outlet passage 312; thus, the insulin liquid 200 in the inlet passage 311 and the outlet passage 312 can be prevented. A countercurrent occurred.

In more detail, when the actuator 31 vibrates upward during the operation, the pressure chamber 313 expands and the volume increases, thereby generating a suction force, causing the valve piece 33a of the inlet passage 311 to be subjected to the pressure difference of the pressure chamber 313. It is adsorbed upwards. At this time, the central portion 331a of the valve piece 33a is quickly disengaged from the state of the convex portion 14a, and the inlet passage 311 is thus opened, so that the insulin liquid 200 in the passage can be introduced into the pressure chamber 313 through the plurality of gaps 333a into the chamber 13a. . When the actuator 32 vibrates downward, the volume of the pressure chamber 313 is compressed, thereby generating a thrust, which urges the valve piece 33b of the outlet passage 312 to receive the thrust, and the central portion 331b of the valve piece 33b is quickly disengaged from the convex portion. In the state of the structure 14b, the outlet channel 312 is thus opened, so that the insulin liquid 200 in the channel can be introduced into the chamber 13b via a plurality of voids 333b, flowed into the outlet channel 312, introduced into the liquid-conducting outlet 314, and introduced into the plurality of micro-needle patches 5 In the hollow microneedles 51, a certain amount of the insulin liquid 200 is further injected into the subcutaneous tissue of the human body. At the same time, the valve piece 33a of the inlet passage 311 is subjected to a compression volume change by the pressure chamber 313 to generate a thrust, thereby causing the central portion 331a of the valve piece 33a to return to the pre-stress of the convex portion structure 14a, closing the inlet passage 311, and the insulin in the passage. The liquid 200 does not generate a backflow from the inlet passage 311.

The present invention is a safe, portable and painless intelligent human body insulin injection liquid supply device 100 for human insulin injection, which provides a device for injecting human insulin in daily life to control blood sugar level at any time, although it is a miniaturized device, The liquid storage chamber 2 stores the human insulin liquid 200 in a limited number of units, and can also be externally introduced into the liquid storage chamber 2 through a pipeline, so that a container of insulin that can be replenished is connected into the liquid storage chamber 2, To form a continuous liquid supply method.

In summary, the human insulin injection device 100 of the present invention is monitored by the sensor 6 When the patient's blood glucose is too high, the actuator 32 that drives the flow-guiding actuation unit 3 changes the volume of the pressure chamber 313, creating a pressure gradient that causes the insulin liquid 200 to flow out of the reservoir chamber 2, through the fluid-conducting channel 31. The microneedle patch 5 is outputted to the microneedle patch 5 under the flow guiding actuating unit 3, and then through the plurality of hollow microneedles 51 of the microneedle patch 5, and the human insulin liquid 200 is automatically injected into the subcutaneous tissue of the patient, which can be used as an automatic supplement for human insulin. Artificial pancreas is used. Moreover, through the setting of the valve switches 4a, 4b, the injection amount of the insulin liquid 200 is accurately controlled to prevent backflow, and the utility model has the advantages of painless, easy to carry and automatic detection of injection timing compared with the conventional insulin injection method, and is highly utilized by the industry.爰 Submit a patent application.

This case has been modified by people who are familiar with the technology, but it is not intended to be protected by the scope of the patent application.

Claims (15)

A liquid supply device for human insulin injection, comprising: a carrier; a liquid storage chamber, is arranged on the carrier for storing an insulin liquid, and has a liquid storage outlet; a flow guiding actuating unit is constructed on the carrier Upper, having a liquid guiding channel, communicating with the liquid storage outlet of the liquid storage chamber, and communicating with a liquid guiding outlet, so that the insulin guiding liquid is driven to transmit the insulin liquid to be output from the liquid guiding outlet; the plurality of valves a switch, the liquid storage outlet and the liquid outlet outlet are respectively provided with a valve switch; a microneedle patch is attached under the flow guiding actuating unit and communicates with the liquid guiding outlet, so that the liquid guiding outlet outputs the insulin liquid Introducing into the microneedle patch, the microneedle patch has a plurality of hollow microneedles for minimally invasive insertion into the human skin to derive the insulin liquid into the subcutaneous tissue; a sensor is disposed on the carrier to resist the human body On the skin, to monitor the blood sugar level in the sweat, and to generate a monitoring value; and a driving chip, the structure is disposed on the carrier to control the actuation of the flow guiding actuating unit, and control the plurality of valve switches Switching state and receiving the monitored value of the sensor; thereby, the microneedle patch is minimally wound into the human skin by the plurality of hollow microneedles, and the sensor detects one of the sweat flowing out of the human skin The monitoring value of the specific blood glucose level is controlled by the driving wafer, and the valve opening of the liquid discharging outlet is controlled, and the valve switch of the liquid discharging outlet is opened to allow the liquid to be stored. The insulin liquid stored in the chamber is outputted from the liquid guiding outlet and introduced into the microneedle patch, and the insulin liquid is infused into the subcutaneous tissue by the plurality of hollow microneedles. The liquid supply device for human insulin injection according to claim 1, wherein the liquid guiding channel of the flow guiding actuating unit is disposed inside the carrier and includes an inlet passage and a pressure. a chamber, an outlet passage, and the liquid outlet, the inlet passage communicates with the liquid storage outlet of the liquid storage chamber, the outlet passage is connected to the liquid outlet, and the inlet passage and the outlet passage are separated from each other, and Passing through the pressure chamber, the flow guiding unit is provided with an actuator, and the actuator covers the pressure chamber to drive and compress the pressure chamber volume formed in the inlet passage and the outlet passage. The insulin liquid is delivered by squeeze flow. The liquid supply device for human insulin injection according to claim 2, wherein the actuator comprises a carrier and an actuating member, the carrier covers the pressure chamber, and the surface is attached to the surface Actuating the element, and the actuating element is deformed to interlock the carrier to generate a deformation resonance to compress the pressure chamber volume formed in the inlet passage and the outlet passage for supplying the insulin liquid to be squeezed. The liquid supply device for human insulin injection according to claim 3, wherein the actuating element is a piezoelectric element. The liquid supply device for injecting human insulin according to the second aspect of the invention, wherein the inlet channel and the outlet channel are further provided with a valve piece and a convex structure for the valve piece to contact the convex structure. A pre-tightening action is performed to control the switching state of the inlet passage and the outlet passage to prevent the insulin liquid from flowing back. The liquid supply device for human insulin injection according to claim 1, wherein the driving wafer comprises a graphene battery to provide a power source. The liquid supply device for human insulin injection according to claim 1, wherein each of the plurality of valve switches comprises a holding member, a sealing member and a displacement member, wherein the displacement member is disposed on the holding member And the sealing member, the sealing member and the displacement member respectively have a plurality of through holes, and the plurality of through holes on the holding member and the displacement member are aligned with each other, and the sealing member is The plurality of through hole positions of the holder form a misalignment misalignment. The liquid supply device for human insulin injection according to claim 7, wherein the displacement member is a charged material, and the holding member is a two-polar conductive material to make the displacement The member maintains a different polarity from the holder and approaches the holder to form the opening of the valve switch. The liquid supply device for human insulin injection according to claim 7, wherein the displacement member is a charged material, and the holder is a two-polar conductive material to maintain the displacement member and the holder. The same polarity, and approaching the seal, constitutes the closing of the valve switch. The liquid supply device for injecting human insulin according to claim 7, wherein the displacement member is a magnetic material, and the holding member is a magnetic material of controlled polarity, so that the displacement member and the displacement member are The retaining members maintain different polarities and approach the retaining member to form the opening of the valve switch. The liquid supply device for injecting human insulin according to claim 7, wherein the displacement member is a magnetic material, and the holding member is a magnetic material of controlled polarity, so that the displacement member and the displacement member are The retaining members maintain the same polarity and approach the seal to form a closure of the valve switch. The liquid supply device for human insulin injection according to any one of claims 8 to 11, wherein the holder is controlled in polarity by the drive wafer. The liquid supply device for human insulin injection according to claim 1, wherein each of the plurality of hollow microneedles of the microneedle patch has an inner diameter of 10 micrometers to 550 micrometers and a length of 400 micrometers. To 900 microns. The liquid supply device for human insulin injection according to claim 1, wherein the plurality of hollow microneedles are arranged in an array, and each of the plurality of hollow microneedles is adjacent to each other by more than 200 micrometers. The liquid supply device for human insulin injection according to claim 1, wherein the plurality of hollow microneedles are made of a cerium oxide material.